Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers

Investigational New Drugs

Volumn 23, Issue 5, 2005, Pages 489-493

  Kindler, Hedy L ^a,d   Tothy, Peter K ^a   Wolff, Robert ^b   McCormack, Richard A ^a   Abbruzzese, James L ^b   Mani, Sridhar ^a,c   Wade Oliver, Kurombi T ^a   Vokes, Everett E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Cholangiocarcinoma; Dolastatin 10; Gallbladder carcinoma; Hepatobiliary cancer; Hepatocellular carcinoma; Pancreatic adenocarcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DOLASTATIN 10; GRANULOCYTE COLONY STIMULATING FACTOR;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; BILIRUBIN BLOOD LEVEL; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DIARRHEA; DRUG FATALITY; DRUG SAFETY; DRUG SCREENING; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GALLBLADDER CARCINOMA; HISTOLOGY; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RECURRENT CANCER; SEPSIS; SURVIVAL TIME; URTICARIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; OLIGOPEPTIDES; PANCREATIC NEOPLASMS;

EID: 23844535643     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-2909-x     Document Type: Article

References (21)

1. Burris HA 3rd, Moore MJ, Andersen J, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15: 2403-2413, 1997
2. Scheithauer W: Review of gemcitabine in biliary tract carcinoma. Semin Oncol 29(6 Suppl 20): 40-45, 2002
3. Misra S, Chaturvedi A, Misra NC, Sharma ID: Carcinoma of the gallbladder. Lancet Oncology 4: 167-176, 2004
4. Nowak AK, Chow PKH, Finlay M: Systemic therapy for advanced hepatocellular carcinoma: A review. Eur J Ca 40: 1474-1484, 2004
5. Pettit GR, Kamano Y, Herald CT, Tuinman AA, Boettner FE, Kizu H, Schmidt JM, Baczynskyj L, Tomer KB, Bontems RJ: The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin-10. J Am Chem Soc 109: 6883-6885, 1987
6. Bai R, Pettit GR, Hamel E: Dolastatin-10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 39: 1941-1949, 1990
7. Aherne GW, Hardcastle A, Valenti M, Bryant A, Rogers P, Pettit GR, Srirangam JK, Kelland: Antitumor evaluation of dolostatins 10 and 15 and their measurement in plasma by radioimmunoassay. Cancer Chemother Pharmacol 38: 225-232, 1996
8. Kalemkerian GP, OU X, Adil MR, Rosati R, Khoulani MM, Madan SK, Pettit GR: Activity of Dolastatin-10 against small cell lung cancer in vitro and in vivo: Induction of apoptosis and bcl-2 modification. Cancer Chemother Pharmacol 43: 507-515, 1999
9. Turner T, Jackson WH, Pettit GR, Wells A, Kraft AS: Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusk. Prostate 34: 175-81, 1998
10. Pitot HC, McElroy EA, Reid JM, Windebank AJ, Sloan JA, Erlichman C, Bagniewski PG, Walker DL, Rubin J, Goldberg RM, Adjei AA, Ames MM: Phase I trial of Dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 5: 525-531, 1999
11. Garteiz DA, Madden T, Beck DE, Huie WR, McManus KT, Abbruzzese JL, Chen W, Newman RA: Quantitation of Dolastatin-10 using HPLC/electrospray ionization mass spectrometry: Application in a phase I clinical trial. Cancer Chemother Pharmacol 41: 299-306, 1998
12. Madden T, Tran HT, Beck D, Huie R, Newman RA, Pusztai L, Wright JJ, Abbruzzese JL: Novel marine-derived anticancer agents: A phase I clinical, pharmacological, and pharmacodynamic study of dolostatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 6: 1293-1301, 2000
13. Simon, R: Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clin. Trial. 10: 1-10. 1989
14. Krug LM, Miller VA, Kalemkerian GP, Kraut MJ, Ng KK, Heelan RT, Pizzo BA, Perez W, McClean N, Kris MG: Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer. Ann Oncol 11: 227-228, 2000
15. Margolin K, Longmate J, Synold TW, Gandara DR, Weber J, Gonzalez R, Johansen MJ, Newman R, Baratta T, Doroshow JH: Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the California Cancer Consortium. Invest New Drugs 19: 335-340, 2001
16. Saad ED, Kraut EH, Hoff PM, Moore DF, Jones D, Pazdur R, Abbruzzese JL: Phase II study of dolastatin-10 as first-line treatment of advanced colorectal cancer. Am J Clin Oncol 25(5): 451-453, 2002
17. Hoffman MA, Blessing JA, Lentz SS: A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 1: 95-8, 2003
18. Vaishampayan U, Glode M, Du W, Kraft A, Hudes G, Wright J, Hussain M: Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Research 6: 4205-4208, 2000
19. Verdier-Pinard P, Kepler JA, Pettit GR, Hamel E: Sustained intracellular retention of dolastatin 10 causes potent antimitotic activity. Mol Pharmacol 57: 180-187, 2000
20. Singh DA, Kindler HL, Eng C, Skoog L, Lenz H-J, Taber D, Vokes EE: Phase II trial of the epothilone B analog BMS-247550 in patients with hepatobiliary cancer. Proc Am Soc Clin Oncol 22: 281, 2003
21. Whitehead RP, McCoy SA, Rivkin SE, Gross HM, Conrad ME, Abbruzzese JL: A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) in patients with advanced pancreas cancer: A Southwest Oncology Group Study. Proc Am Soc Clin Oncol 23: 315, 2004